TABLE 3.
Baseline and posttreatment raw scores for neuropsychological, behavioral, and physiological measures
| Baseline | Atomoxetine | Placebo | Num df | ATS | P | |
|---|---|---|---|---|---|---|
| Neuropsychological tasks | ||||||
| Verbal Paired Associates | 17.3 (9.0) | 21.2 (8.0) | 22 (6.5) | 1.89 | 8.04 | 0.0004 |
| Digit Symbol Coding | 65.5 (16.5) | 69.8 (16.1) | 73.1 (21.5) | 1.98 | 1.90 | 0.15 |
| Symbol Search | 30.1 (6.9) | 34.8 (9.5) | 32.6 (10.2) | 1.91 | 2.12 | 0.12 |
| COWAT | 44.8 (12.9) | 44.9 (13.1) | 44.9 (12.7) | 1.77 | 0.13 | 0.85 |
| Letter-Number Sequencing | 11.8 (3.0) | 12.3 (2.1) | 12.8 (2.2) | 1.61 | 1.27 | 0.28 |
| Behavioral assessments | ||||||
| Beck Depression | 6.53 (4.2) | 4.5 (4.2) | 5.4 (4.9) | 1.66 | 1.29 | 0.27 |
| Beck Anxiety | 5.3 (5.3) | 6.5 (6.4) | 7.0 (6.3) | 1.57 | 0.72 | 0.46 |
| POMS-Tension | 2.93 (1.9) | 5.1 (7.9) | 4.4 (4.5) | 1.49 | 0.04 | 0.92 |
| POMS-Depression | 3.29 (5.2) | 3.6 (10.1) | 1.7 (2.6) | 1.64 | 0.38 | 0.91 |
| POMS-Anger | 1.79 (3.0) | 3.2 (7.5) | 1.4 (3.2) | 1.61 | 0.33 | 0.67 |
| POMS-Fatigue | 4.14 (4.9) | 4.0 (7.3) | 4.1 (4.6) | 1.31 | 1.19 | 0.29 |
| POMS-Vigor | 13.7 (5.5) | 14.9 (7.8) | 14.3 (7.3) | 1.91 | 0.61 | 0.54 |
| POMS-Confusion | 4.64 (2.6) | 4.1 (4.6) | 3.8 (2.2) | 1.84 | 0.80 | 0.44 |
| Physiological monitoring | ||||||
| Systolic BP, mm Hg | 118.8 (12.5) | 116.7 (11.3) | 120.3 (8.5) | 1.83 | 0.62 | 0.52 |
| Diastolic BP, mm Hg | 74 (10.0) | 69.8 (7.7) | 70.7 (5.2) | 1.66 | 0.62 | 0.51 |
| Heart rate, beats/min | 63 (3.2) | 68.8 (8.2) | 66.3 (5.5) | 1.76 | 1.26 | 0.28 |
| Weight, lb | 160.1 (41.8) | 158.1 (44.4) | 159.8 (42.6) | 1.91 | 0.85 | 0.42 |
Baseline, Atomexetine, and Placebo data given as mean (SD). ATS, analysis of variance-type statistics; COWAT, Controlled Oral Word Association Test; POMS, Profile of Mood States; BP, blood pressure.